LncRNA-HEIH is a Novel Diagnostic and Predictive Biomarker in Gastric Cancer

Abstract

Background: Gastric cancer (GC) is associated with a high mortality rate. Long noncoding RNA (lncRNA)high expression in hepatocellular carcinoma (HEIH) has recently gained interest as a marker for the detection of several cancer types. This study was designed to uncover the function of lncRNA-HEIH in GC. Materials and Methods: Oncomine was used to analyze HEIH expression in cancerous and paired noncancerous tissues of GC patients. Subsequently, the expression levels of HEIH in GC cells was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, the effects of HEIH expression level on clinicopathological parameters and prognosis were further studied by statistical analysis and Kaplan-Meier survival curves. GC cell proliferation and the influence of HEIH on the sensitivity of cells to oxaliplatin following HEIH knockdown were assessed using sulforhodamine blue (SRB) assays in the MKN45 and AGS cell lines. In addition, the expression levels of p53 were detected by RT-qPCR following knockdown of HEIH. Results: The lncRNA-HEIH was highly expressed in both GC tissues and GC cell lines. Patients with high HEIH expression were associated with medium-high differentiation ( p = 0.0058), distant metastasis (M, p = 0.0378), lymph node metastasis (N, p = 0.0083), and a deeper tumor invasion (T, p = 0.0204). Elevated expression levels of HEIH in GC patients were associated with a worse prognosis compared to GC patients with low HEIH expression. This finding was supported by the parameters of overall survival ( p = 3.3e-06), first progression ( p = 0.00028), and postprogression ( p = 1.5e-08). Downregulation of HEIH expression inhibited cell proliferation, enhanced oxaliplatin sensitivity, and induced the expression of p53 in MKN45 and AGC cells. Conclusion: These findings provide evidence that HEIH may be useful as a prognostic biomarker in GC. This lncRNA may also serve as a potential therapeutic target in GC patients.

Over-expression of long non-coding RNA insulin-like growth factor 2-antisense suppressed hepatocellular carcinoma cell proliferation and metastasis by regulating the microRNA-520h/cyclin-dependent kinase inhibitor 1A signaling pathway

“…Increasing studies have verified that long noncoding RNAs (lncRNAs) play key roles during the development of multiple human cancers [ 3–5 ]. Studies have reported that IGF2-AS is a biomarker for cancer diagnosis and prognosis, including as a tumor suppressor in breast cancer [ 6 ], a promotor of glycolysis and apoptosis of gastric cancer cells via targeting miR-195/CREB1 axis [ 7 ], a potential target for colorectal cancer (CRC) treatment [ 8 ], as well as the prognosis and metastasis of gastric adenocarcinoma via serving as a ceRNA of miR-503 to regulate SHOX2 9 .…”

High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

“…25 LncRNA HEIH high expression in gastric cancer patients is closely related to medium-high differentiation, distant metastasis, lymph node metastasis, and deeper tumor invasion. 45 Altogether, high expression of lncRNA HEIH is associated with poorer clinical indicators and higher cancer staging.…”

Long non-coding RNA HEIH: a novel tumor activator in multiple cancers

“…Tumors of the digestive system, when combined together, account for more new cases and deaths per year than tumors arising in any other system of the body and their incidence continues to increase [ 22 ]. Mounting evidences have confirmed that HEIH as an oncogene, is abnormally expressed in numerous digestive system cancers, such as hepatocellular carcinoma (HCC) [ 21 , 23 – 27 ], tongue squamous cell carcinoma(TSCC) [ 28 ], gastric cancer (GC) [ 29 – 31 ], esophageal cancer (EC) [ 32 – 34 ], colorectal cancer (CRC) [ 35 ], and cholangiocarcinoma [ 20 ]. But so far, no studies have yet examined the function of HEIH in cancers of the pancreas and other digestive system organ.…”